DPP4 and myocardial infarction: It was shown that the treatment with DPP4 inhibitor sitagliptin improved cardiovascular outcomes after myocardial infarction in non-diabetic mice; similar results were also obtained in non-diabetic DPP4−/− mice (Sauve et al., 2010).